[Form 4] Catheter Precision, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Catheter Precision, Inc. (VTAK) reported an insider transaction in which a company director was granted 50,000 stock options with an exercise price of $0.18. The options were granted on the reported transaction date and vest one-third each year beginning on the first anniversary of the grant. The options are exercisable through the expiration date in 2035, and the reporting person holds 50,000 underlying shares post-transaction.

This disclosure is a routine director equity award that creates long-term option-based compensation and the right to acquire 50,000 shares at the stated strike price subject to the vesting schedule.

Insights

Securities Analyst

TL;DR: Routine director option grant; modest in size, long-dated, and structured with multi-year vesting.

The grant of 50,000 options at a $0.18 exercise price is a standard mechanism to align a director's interests with shareholders. Vesting one-third per year encourages continued service. The long-term expiration through 2035 provides extended upside potential for the holder but delays full potential dilution until vested and exercised. Based solely on the filing, the transaction appears procedural and not immediately material to capital structure.

Corporate Governance Expert

TL;DR: Governance-standard equity award to a director with time-based vesting; transparency maintained via Form 4 disclosure.

The Form 4 reports an option award with clear vesting terms: 1/3 per year starting after one year, and an expiration date in 2035. This structure supports retention and aligns incentives without immediate share issuance. The filing fulfills Section 16 disclosure requirements and provides investors with the necessary details to assess director compensation timing and potential future share issuance.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

COLOMBATTO MARTIN J

(Last) (First) (Middle)

1670 HIGHWAY 160 WEST

SUITE 205

(Street)

FORT MILL SC 29708

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Catheter Precision, Inc. [ VTAK ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
08/12/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Options (Right to Buy)	$0.18	08/12/2025		A		50,000		(1)	08/12/2035	Common Stock	50,000	$0	50,000	D

Explanation of Responses:

1. Options vests 1/3 per year beginning on first anniversary of grant date.

	/s/ Martin Colombatto	08/14/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.